Advertisement
YOU ARE HERE: LAT HomeCollectionsCortex Pharmaceuticals Inc
IN THE NEWS

Cortex Pharmaceuticals Inc

BUSINESS
February 18, 1999
Cortex Pharmaceuticals Inc.: The Irvine developer of therapies for neurological and psychiatric disorders said it lost $945,600, or 8 cents a share, in the fiscal second quarter, compared with a net loss of $1.3 million, or 14 cents a share, for the same period a year earlier. No revenues were recorded.
Advertisement
BUSINESS
December 1, 1998 | BARBARA MARSH, Barbara Marsh covers health care for The Times. She can be reached at (714) 966-7762 and at barbara.marsh@latimes.com
It may not be much, but it's the thought that counts for Cortex Pharmaceuticals Inc. The tiny Irvine developer of drug therapies for neurological and psychiatric disorders just landed a $100,000 grant from the National Institutes of Health to help develop a treatment for schizophrenia. The money will help fund the company's search for new compounds that could be administered once a day.
BUSINESS
November 9, 1998
Irvine-based Cortex Pharmaceuticals Inc. posted a loss of $1.2 million, or 12 cents a share, for the fiscal first quarter ended Sept. 30, compared with a loss of $1.3 million, or 14 cents a share, for the same period a year ago. The company reported no revenue.
BUSINESS
October 24, 1998 | Barbara Marsh
Cortex Pharmaceuticals Inc., in danger of being delisted on the Nasdaq SmallCap Market, said Friday that it hopes to raise additional capital from prospective corporate partners. The Irvine-based developer of drug therapies for neurological and psychiatric disorders said in a statement that it is in talks with some investors but did not identify them. If the Nasdaq doesn't approve of Cortex's plan, the exchange will issue a formal notice of delisting.
BUSINESS
September 30, 1998
Cortex Pharmaceuticals Inc.: The Irvine developer of treatments for neurological and other psychiatric disorders posted a net loss of $1.17 million, or 12 cents a share, for the fourth quarter, ended June 30, compared with a net loss of $1.28 million, or 25 cents a share, for the same period a year earlier. The company reported no revenue. For the year, Cortex lost $5.3 million, or 55 cents a share, compared with a loss of $4.
BUSINESS
May 22, 1998 | Times Staff and Wire Reports
One day after doubling in price, NeoTherapeutics Inc.'s stock fell 31% Thursday after the biotechnology company elaborated on the risks and costs of its attempt to develop a drug for Alzheimer's disease. NeoTherapeutics fell $6 to $13.25 as 3.2 million shares were traded. On Wednesday, the stock doubled to $19.25 after reporting encouraging results for a treatment of Alzheimer's disease. Officials at the Irvine company said the results reported Wednesday had been disclosed previously.
BUSINESS
May 21, 1998 | LESLIE EARNEST, SPECIAL TO THE TIMES
Two Orange County drug developers became the latest firms swept up Wednesday in investors' euphoria over companies working on treatments for a variety of serious diseases. NeoTherapeutics Inc.'s stock more than doubled to $19.25 a share from $9.60, making it the biggest percentage gainer in U.S. markets, after the Irvine company reported encouraging results for a treatment for Alzheimer's disease. Earlier in the session, the stock hit an all-time high of $21.
BUSINESS
May 21, 1998 | From Times Staff and Wire Reports
Two Orange County drug developers Wednesday became the latest firms swept up in investors' euphoria over companies working on treatments for a variety of serious diseases. NeoTherapeutics Inc.'s stock more than doubled to $19.25 a share from $9.60, making it the biggest percentage gainer in U.S. markets, after the Irvine company reported encouraging results for an Alzheimer's disease treatment.
BUSINESS
May 12, 1998 | Dow Jones
Cortex Pharmaceuticals Inc.'s stock surged 23% Monday after the Irvine company said it has signed an exclusive licensing agreement with the University of California for commercial rights to potential schizophrenia treatments. Cortex said the new agreement enables it to develop products for treating schizophrenia that incorporate AMPA receptor modulating technology.
Los Angeles Times Articles
|